Teva Pharmaceutical Gains New Confidence from Miuzho Amid Restructuring Turnover at Headquarters

After talking with Teva Pharmaceutical (NYSE:TEVA) management, Mizuho analyst Irina Rivkind Koffler is more positive on the rebounding Israeli pharma giant in the midst of corporate restructuring plans that bode well for delaying a credit downgrade.

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts